Summit Therapeutics Stock Rises on Partner Cancer Trial Data

By EC Assets · Published 26 August 2026

Summit Therapeutics Inc. stock experienced a jump following data from a partner's cancer trial. The company is involved in a clinical trial collaboration with Arcus Biosciences, Inc. This partnership focuses on combining Arcus's casdatifan with other compounds. The collaboration between Arcus Biosciences, Inc. and Summit Therapeutics Inc. was announced on July 22. This partnership aims to create a new treatment standard for cancer. Arcus's casdatifan is an investigational HIF-2α. Leerink Partners initiated coverage on Summit stock. Analyst Daina Graybosch assigned an "underperform" rating to the stock, indicating a sell recommendation. This article is intended for informational purposes only. It does not constitute investment advice.